Valuation: Rapport Therapeutics, Inc.

Market Cap 2.02B 1.75B 1.63B 1.5B 2.84B 192B 2.87B 19.26B 7.53B 95.97B 7.58B 7.41B 318B P/E 2026 *
-12.2x
P/E 2027 * -10.1x
Enterprise Value 1.8B 1.57B 1.46B 1.34B 2.54B 172B 2.57B 17.23B 6.73B 85.82B 6.78B 6.63B 284B EV / Sales 2026 *
90.2x
EV / Sales 2027 * -
Free-Float
95.41%
Yield 2026 *
-
Yield 2027 * -
1 day-1.21%
1 week+0.74%
Current month+0.65%
1 month+6.94%
3 months+15.89%
6 months+61.43%
Current year+35.94%
1 week 39.75
Extreme 39.75
42.88
1 month 38.48
Extreme 38.48
44.28
Current year 25.21
Extreme 25.21
44.28
1 year 13.62
Extreme 13.62
44.28
3 years 6.43
Extreme 6.43
44.28
5 years 6.43
Extreme 6.43
44.28
10 years 6.43
Extreme 6.43
44.28
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 61 31/12/2022
Chief Executive Officer 48 31/01/2023
Director of Finance/CFO 58 31/10/2023
Director TitleAgeSince
Director/Board Member 61 22/08/2023
Director/Board Member 48 28/02/2023
Director/Board Member 54 31/01/2022
Date Insider Type Main position Quantity % Market Cap.
27/07/26 Sell

Chief Executive Officer

-2,210 0.0046%
14/07/26 Sell

Chief Executive Officer

-8,210 0.0172%
30/06/26 Sell

Chief Operating Officer

-10,000 0.0209%
Change 5-day change 1-year change 3-year change Capi.($)
-1.21%+0.74%+185.83% - 2.02B
+0.90%-2.33%+0.68%+14.52% 48B
+0.92%+7.29%+405.64%+554.91% 41.13B
+3.23%-5.03%+27.82%+7.21% 37.56B
+2.36%+0.98%+7.55%+76.21% 35.91B
+2.42%+7.27%+14.90%+44.79% 29.86B
+0.57%-2.87% - - 16.12B
+1.38%-0.42%+33.51%+123.70% 16.05B
+1.25%+1.52%+4.62%+18.66% 13.76B
+4.86%-8.15%-1.40%-34.95% 12.1B
Average +1.54%-1.87%+75.46%+100.63% 25.25B
Weighted average by Cap. +1.64%-1.28%+82.22%+126.65%

Financials

2026 *2027 *
Net sales 20M 17.37M 16.19M 14.87M 28.13M 1.9B 28.44M 191M 74.62M 951M 75.11M 73.46M 3.15B -
Net income -166M -144M -135M -124M -234M -15.81B -236M -1.59B -620M -7.91B -624M -611M -26.19B -219M -190M -177M -163M -307M -20.79B -311M -2.09B -816M -10.39B -821M -803M -34.44B
Net Debt -214M -185M -173M -159M -300M -20.31B -304M -2.04B -797M -10.15B -802M -784M -33.65B -306M -266M -248M -228M -431M -29.14B -436M -2.92B -1.14B -14.57B -1.15B -1.13B -48.27B
Logo Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc. is a clinical-stage biotechnology company engaged in discovering and developing small-molecule precision medicines for patients with neurological or psychiatric disorders. It has made discoveries related to the function of receptor-associated proteins (RAPs) in the brain. Its RAP technology platform enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Its precision neuroscience pipeline includes its lead investigational drug, RAP-219, designed to achieve neuroanatomical specificity through its selective targeting of a RAP expressed in only discrete regions of the brain. It is pursuing RAP-219 as a treatment for patients with focal onset seizures, primary generalized tonic-clonic seizures and bipolar mania. Additional preclinical and late-stage discovery stage programs are also underway, including chronic pain and hearing disorders.
Employees
84
Date Price Change Volume
05/08/26 US$41.23 -2.30% 58,144
04/08/26 US$42.20 +3.46% 398,035
03/08/26 US$40.79 -0.46% 315,229
31/07/26 US$40.98 -4.21% 240,878
30/07/26 US$42.78 +4.49% 216,872
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
42.20USD
Average target price
58.59USD
Spread / Average Target
+38.83%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RAPP Stock